NYSE:CRL Charles River Laboratories International (CRL) Stock Price, News & Analysis $340.64 -4.23 (-1.23%) Closing price 03:59 PM EasternExtended Trading$339.86 -0.79 (-0.23%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Charles River Laboratories International Stock (NYSE:CRL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRL alerts:Sign Up Key Stats Today's Range$337.78▼$351.2150-Day Range$272.68▼$344.8052-Week Range$146.20▼$351.21Volume2.12 million shsAverage Volume944,288 shsMarket Capitalization$16.26 billionP/E RatioN/ADividend YieldN/APrice Target$302.33Consensus RatingModerate Buy Company Overview Charles River Laboratories International, Inc. is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support. Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs. Charles River also provides microbiology, endotoxin and other quality-control testing services, as well as contract development and manufacturing capabilities for certain drug products and biological materials. Founded in 1947, Charles River Laboratories is headquartered in Wilmington, Massachusetts, and serves customers through operations in North America, Europe, Asia and other international markets. Its customers include pharmaceutical and biotechnology companies, academic institutions, government agencies and other organizations involved in life-sciences research and development.AI Generated. May Contain Errors. Read More Charles River Laboratories International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreCRL MarketRank™: 2.638833664675 of 5 starsCharles River Laboratories International scored higher than 53% of companies evaluated by MarketBeat, and ranked 472nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingCharles River Laboratories International has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 12 buy ratings, 2 hold ratings, and 1 sell rating.Downside RiskCharles River Laboratories International has a consensus price target of $302.33, representing about 11.5% downside from its current price of $341.65.Amount of Analyst CoverageCharles River Laboratories International has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Charles River Laboratories International's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth10.72% Earnings GrowthEarnings for Charles River Laboratories International are expected to grow by 10.72% in the coming year, from $11.38 to $12.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Charles River Laboratories International is -70.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Charles River Laboratories International is -70.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCharles River Laboratories International has a PEG Ratio of 2.95. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCharles River Laboratories International has a P/B Ratio of 5.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Charles River Laboratories International's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.11% of the float of Charles River Laboratories International has been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.69, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently increased by 29.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCharles River Laboratories International does not currently pay a dividend.Dividend GrowthCharles River Laboratories International does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.79 News SentimentCharles River Laboratories International has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Charles River Laboratories International this week, compared to 5 articles on an average week.Search Interest16 people have searched for CRL on MarketBeat in the last 30 days. This is an increase of 1,500% compared to the previous 30 days.MarketBeat Follows3 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Charles River Laboratories International insiders have sold 875,285.61% more of their company's stock than they have bought. Specifically, they have bought $2,974.00 in company stock and sold $26,033,968.00 in company stock.Percentage Held by Insiders1.30% of the stock of Charles River Laboratories International is held by insiders.Percentage Held by Institutions98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Charles River Laboratories International's insider trading history. Receive CRL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRL Stock News HeadlinesCharles River Laboratories International (CRL) Partners With Magellan As Valuation Questions Linger3 hours ago | finance.yahoo.comDrug development inputs & services stocks Q2 in review: Charles River Laboratories (NYSE:CRL) vs peersOctober 16, 2026 | msn.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 22 at 1:00 AM | Weiss Ratings (Ad)ETFs Are Net Sellers of Charles River (CRL) on WednesdayOctober 16, 2026 | finance.yahoo.comCharles River Laboratories International Inc. stock underperforms Thursday when compared to competitors despite daily gainsOctober 15, 2026 | marketwatch.comMorgan Stanley Adjusts Price Target on Charles River Laboratories International to $340 From $300October 12, 2026 | marketscreener.comMCharles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference CallOctober 9, 2026 | finance.yahoo.comCharles River and Autolomous Partner to Transform Laboratory Execution SystemsOctober 6, 2026 | marketscreener.comMSee More Headlines CRL Stock Analysis - Frequently Asked Questions How have CRL shares performed this year? Charles River Laboratories International's stock was trading at $199.62 at the beginning of 2026. Since then, CRL stock has increased by 71.2% and is now trading at $341.6520. How were Charles River Laboratories International's earnings last quarter? Charles River Laboratories International, Inc. (NYSE:CRL) released its quarterly earnings results on Wednesday, August, 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. The firm's revenue for the quarter was down 2.7% compared to the same quarter last year. Read the conference call transcript. Does Charles River Laboratories International have any subsidiaries? The following companies are subsidiaries of Charles River Laboratories International: Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and more. Who are Charles River Laboratories International's major shareholders? Charles River Laboratories International's top institutional shareholders include Cooke & Bieler LP (0.91%), Assenagon Asset Management S.A. (0.43%), State of Alaska Department of Revenue (0.23%) and Confluence Investment Management LLC (0.17%). Insiders that own company stock include Birgit Girshick, James C Foster, Victoria L Creamer, Glenn Coleman, Joseph W Laplume, William D Barbo, Richard F Wallman, Michael Gunnar Knell, George Massaro, Shannon M Parisotto and Nancy C Andrews. View institutional ownership trends. How do I buy shares of Charles River Laboratories International? Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Charles River Laboratories International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), PayPal (PYPL), JPMorgan Chase & Co. (JPM), Pfizer (PFE) and Adobe (ADBE). Company Calendar Last Earnings8/05/2026Today10/22/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CRL's financial health is in the Green zone, according to TradeSmith. CRL has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CRL CIK1100682 Webwww.criver.com Phone(781) 222-6000Fax978-988-5665Employees19,700Year Founded1947Price Target and Rating Average Price Target for Charles River Laboratories International$302.33 High Price Target$357.00 Low Price Target$219.00 Potential Upside/Downside-11.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.85) Trailing P/E RatioN/A Forward P/E Ratio29.86 P/E Growth2.95Net Income-$144.34 million Net Margins-5.96% Pretax Margin-4.59% Return on Equity15.75% Return on Assets6.51% Debt Debt-to-Equity Ratio0.92 Current Ratio1.35 Quick Ratio1.04 Sales & Book Value Annual Sales$4.02 billion Price / Sales4.04 Cash Flow$23.64 per share Price / Cash Flow14.37 Book Value$64.39 per share Price / Book5.28Miscellaneous Outstanding Shares47,740,000Free Float47,118,000Market Cap$16.22 billion OptionableOptionable Beta1.40 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:CRL) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Charles River Laboratories International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles River Laboratories International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
